Kyle Woodley

Kyle Woodley

Senior Investing Editor, Kiplinger

Kyle Woodley is the Senior Investing Editor of Kiplinger.com. His articles covering stock picks, exchange-traded funds and mutual funds have been featured on MSN, Nasdaq and U.S. News & World Report. He also has appeared on Fox Business Network.

He previously was Managing Editor of InvestorPlace.com, and an award-winning designer and copy editor with Gannett. He also is a graduate of Ohio State University.

Kyle can be reached at kwoodley@kiplinger.com, or you can follow him on Twitter at @KyleWoodley.

Recent Articles

Biotech Movers: Chelsea Doubles, Vivus Dips

By Kyle Woodley, Senior Investing Editor, Kiplinger

Last week, Vivus slipped on a rejection from European regulators. Plus, find out why Chelsea Therapeutics and Infinity Pharmaceuticals soared.

Biotech Movers: Big Bumps All Around

By Kyle Woodley, Senior Investing Editor, Kiplinger

Last week, big names from Ziopharm Oncology to StemCells posted stellar gains, while Amicus Therapeutics shaked the positive trend with a hearty tumble.

Still Wild for BWLD

By Kyle Woodley, Senior Investing Editor, Kiplinger

Sure, the company faces headwinds -- uncertainty about the minimum wage and higher input costs among them -- but Buffalo Wild Wings has carved out a dedicated niche that's unlikely to fade anytime soon.

Top 10 Dow Dividend Stocks for February

By Kyle Woodley, Senior Investing Editor, Kiplinger

Income investors could do a lot worse than buying into these venerable blue chips -- especially the stock that continues to hold the crown.

Biotech Movers: A Doubler for Opexa

By Kyle Woodley, Senior Investing Editor, Kiplinger

A good week for little guys Opexa Therapeutics and Hyperion Therapeutics and giant Biogen. But Hemispherx BioPharma and BioCryst Pharmaceuticals had downers.

Load More